Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana Life Sciences’ research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company anticipates that Bcl-3 will progress to clinical trials in 2016.
London, GB
Size (employees)
5 (est)+25%
Tiziana Life Sciences was founded in 2013 and is headquartered in London, GB

Tiziana Life Sciences Office Locations

Tiziana Life Sciences has an office in London
London, GB (HQ)
18 South St

Tiziana Life Sciences Data and Metrics

Tiziana Life Sciences Financial Metrics

Tiziana Life Sciences's revenue was reported to be (£6.3 m) in FY, 2015 which is a 692% increase from the previous period.
£, GBP

Revenue (FY, 2015)

(6.3 m)

Revenue growth (FY, 2014 - FY, 2015), %


Net income (FY, 2015)

(8.6 m)

Market capitalization (13-Jun-2017)

165.8 m

Closing share price (13-Jun-2017)


Cash (31-Dec-2015)

8.9 m
Tiziana Life Sciences's current market capitalization is £165.8 m.
£, GBPFY, 2014FY, 2015


(794 k)(6.3 m)

Revenue growth, %


Pre tax profit

(3.4 m)(8.6 m)

Net Income

(3.3 m)(8.6 m)
£, GBPFY, 2014FY, 2015


2.3 m8.9 m

Current Assets

2.5 m9.3 m

Total Assets

2.5 m9.3 m

Accounts Payable

41 k314 k

Current Liabilities

683 k746 k

Retained Earnings

(3.3 m)(8.6 m)

Total Equity

1.8 m8.5 m

Financial Leverage

1.4 x1.1 x
£, GBPFY, 2014FY, 2015

Cash From Operating Activities

(2.2 m)(5.5 m)

Cash From Financing Activities

4.4 m12.1 m

Income Taxes Paid

60 k
£, GBPY, 2015


(1.6 m)

Financial Leverage

1.1 x

Tiziana Life Sciences Market Value History

Tiziana Life Sciences Online and Social Media Presence

Tiziana Life Sciences News and Updates

Tiziana Life Sciences Company Life and Culture

You may also be interested in